{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_6500", "batch_size": 200, "batch_pos": 86, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment describes research history using neutral language.", "method": "llm_batch", "batch_id": "batch_2_19796", "batch_size": 200, "batch_pos": 65, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment discusses research history but uses neither a moderate verb nor scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_19928", "batch_size": 200, "batch_pos": 200, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_7212", "batch_size": 200, "batch_pos": 192, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports Moderna's research began with flu but provides no explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_6876", "batch_size": 200, "batch_pos": 189, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser word found.", "method": "llm_batch", "batch_id": "batch_6_17848", "batch_size": 200, "batch_pos": 145, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment describes research beginning, no bare negation.", "method": "llm_batch", "batch_id": "batch_7_13360", "batch_size": 200, "batch_pos": 131, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes the history of research related to vaccine development capability (\"research actually began\").", "method": "llm_batch", "batch_id": "batch_8_5816", "batch_size": 200, "batch_pos": 161, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
